Free tool
FAERS Monitor: Symlin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021332 or its brand name (Symlin, Pramlintide Acetate). Reports on generic versions are filed under their own applications.
Reports
102
Serious
51
50% of reports
Hospitalization
25
Death reported
10
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased15
- acute kidney injury11
- chronic kidney disease11
- nausea9
- dyspnoea8
- fatigue8
- hypertension7
- renal failure7
- weight decreased7
- chest pain6
- diarrhoea6
- drug ineffective6
- osteoarthritis6
- weight increased6
- back pain5
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 5 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 9 |
| 2013 | 8 |
| 2014 | 8 |
| 2015 | 11 |
| 2016 | 13 |
| 2017 | 5 |
| 2018 | 9 |
| 2019 | 10 |
| 2020 | 8 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,057 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 11 | 29.9 | 17.1 | 280 |
| osteoarthritisSignal | 6 | 29.2 | 13.4 | 137 |
| blood glucose increasedSignal | 15 | 16.4 | 10.3 | 204 |
| acute kidney injurySignal | 11 | 14.8 | 8.5 | 129 |
| renal failureSignal | 7 | 10.9 | 5.3 | 54 |
| hypertensionSignal | 7 | 6.8 | 3.3 | 29 |
| chest painSignal | 6 | 6.7 | 3.1 | 24 |
| weight increasedSignal | 6 | 5.5 | 2.5 | 18 |
| weight decreasedSignal | 7 | 5.2 | 2.5 | 20 |
| back painSignal | 5 | 4.4 | 1.9 | 10 |
| dyspnoeaSignal | 8 | 2.9 | 1.5 | 8 |
| nauseaSignal | 9 | 2.3 | 1.3 | 6 |
| fatigue | 8 | 2.1 | 1.1 | 4 |
| diarrhoea | 6 | 1.9 | 0.9 | 2 |
| drug ineffective | 6 | 0.9 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.